… mg/L/hr (24 mg/L/wk) over the stay. Two nonobese patients and one obese patient needed
… hemofiltration and PIP concentration ranged in these patients from 40 to 370 mg/L (Fig. 2, A …

… patients, including obese and morbidly obese patients. Critically ill patients who received
piperacillin-tazobactam … Monte Carlo dosing simulations to identify optimized dosing regimens …

… Creatinine clearance (CrCl) was calculated using a lean body weight estimate formula in
the Cockcroft–Gault equation based on its performance in morbid obesity [20]. …

… currently used piperacillin/tazobactam dosing regimens in obese and nonobese patients. For
… I Standard body weight, II lower BMI threshold for morbid obesity, III healthy renal function […

… received continuous infusions of piperacillin/tazobactam, … infusion of piperacillin/tazobactam
in obese patients. In 31 … Single-dose cefepime in morbidly obese patients before bariatric …

… there were morbidly obese patients (BMI ≥ 40 … doses for obese patients with cancer have
been rare in Korea, which lends further meaning to our study that analyzes this specific patient …

… BMI groups (Fig. 5). Our data do not support that an increase in renal clearance accounts
for elevated CL PIP in morbidly obese patients… in obese patients [50, 51] may impose dosing …

… and piperacillin-tazobactam for obese and non-obese patients with Enterobacteriaceae
bacteremia. Obese patients … This optimized dosing, coupled with the relatively low median MIC …

… of any available dosing guidelines for critically ill obese patients. … of β-lactam dosing in
critically ill obese patients, the certainty of … Meropenem and piperacillin/tazobactam were dosed …

… (35) Most (80%) patients received extendedinfusion piperacillin/tazobactam (3.375gq 8 hours
… non-obese, obese, and morbidly obese patients and that weight alone should not prompt …